Elsevier

Experimental Gerontology

Volume 68, August 2015, Pages 19-25
Experimental Gerontology

Clinical strategies and animal models for developing senolytic agents

https://doi.org/10.1016/j.exger.2014.10.012Get rights and content

Highlights

  • ā€¢

    Scenarios for proof-of-concept clinical studies of senolytic agents are proposed.

  • ā€¢

    Animal models for testing candidate senolytics are considered.

  • ā€¢

    Models are needed that reflect potential clinical applications of senolytic agents.

  • ā€¢

    Animal models for determining dosing intervals and side effects will be important.

  • ā€¢

    Whether senescent cell removal related to drugs is the cause of phenotype resolution must be proven.

Abstract

Aging is associated with increasing predisposition to multiple chronic diseases. One fundamental aging process that is often operative at sites of the pathology underlying chronic age-related diseases is cellular senescence. Small molecule senolytic agents are being developed. For successful drug development: 1) appropriate animal models of human age-related diseases need to be devised. 2) Models have to be made in which it can be proven that beneficial phenotypic effects are actually caused through clearing senescent cells by putative senolytic agents, as opposed to ā€œoff-targetā€ effects of these agents on non-senescent cells. 3) Models are needed to test efficacy of drugs and to uncover potential side effects of senolytic agents. Development of the optimal animal models and clinical trial paradigms for senolytic agents warrants an intensive effort, since senolytic agents, if successful in delaying, preventing, alleviating, or reversing age-related diseases as a group would be transformative.

Introduction

Aging is associated with increasing predisposition to multiple chronic diseases: atherosclerosis, cancers, dementias, diabetes, arthritis, and many others (Goldman et al., 2013, Kirkland, 2013a, Kirkland, 2013b, Research, A.f.A., 2012). Chronological age is the biggest risk factor for many of these diseases and in some cases is a better predictor than all other known risk factors combined. One fundamental aging process that is often operative at sites of pathology underlying chronic age-related diseases is cellular senescence (Kirkland, 2013a, Tchkonia et al., 2013).

Cellular senescence refers to the essentially irreversible cell cycle arrest caused by potentially oncogenic and metabolic insults (Tchkonia et al., 2013). Senescent cells can acquire a senescence-associated secretory phenotype (SASP) that involves release of pro-inflammatory cytokines, chemokines, pro-thrombotic factors, and extracellular matrix proteases that cause tissue damage, as well as extracellular matrix proteins that can contribute to dysfunctional tissue architecture or fibrosis. Thus, the adverse pathogenic mechanisms at the tissue level that could be promoted by cellular senescence include chronic inflammation, loss of functional progenitor cells, clotting, and extracellular matrix dysfunction.

Senescent cells accumulate in multiple tissues with advancing age (Tchkonia et al., 2013, Waaijer et al., 2012). Senescent cell burden is, in turn, associated with lifespan. At 18Ā months of age, long-lived Ames dwarf, Snell dwarf, and growth hormone receptor knockout (GHRKO) mice have fewer senescent cells in their fat tissue than age-matched control wild-type animals, while short lived growth hormone over-expressing mice have more (Stout et al., 2014). Caloric restriction sufficient to increase lifespan in mice is associated with decreased expression of p16Ink4a, a senescence marker, in multiple tissues compared to ad libitum-fed animals (Krishnamurthy et al., 2004). Progeroid mice, including mouse models of Werner and Hutchinsonā€“Guilford progerias, as well as Klotho-deficient, Erccāˆ’/āˆ’, and BubR1H/H mice have increased senescent cells (Baker et al., 2008, Chen et al., 2013, Eren et al., 2014b, Tchkonia et al., 2013). In comparisons across longer- vs. short-lived mouse cohorts, senescent cell accumulation in liver and intestinal crypts predicts mean and maximum lifespan (Jurk et al., 2014). Cellular senescence can occur at any point during life, even in blastocysts (Meuter et al., 2014) and in the placenta (Rajagopalan and Long, 2012). Indeed, senescence is important in remodeling during embryogenesis (Munoz-Espin et al., 2013, Storer et al., 2013).

These associations between cellular senescence, aging, and age-related pathologies prompted testing if senescent cell clearance ameliorates dysfunction. Genetically targeting senescent cells in INK-ATTAC;BubR1H/H progeroid mice that express a drug-activatable ā€œsuicideā€ gene only in senescent cells enhanced healthspan (Baker et al., 2011), the portion of the lifespan during which freedom from pain, disability, and dependence is enjoyed (Kirkland and Peterson, 2009). Even clearing only around 30% of senescent cells from these mice led to partial reversal of age-related lipodystrophy and decreased progression of frailty, sarcopenia, and cataract formation (Baker et al., 2011, Tchkonia et al., 2013).

These findings have spurred development of small molecule senolytic agents and other approaches to decrease senescent cell burden, including peptides, RNA interference, and vaccines. For this effort to succeed: 1) appropriate animal models of human age-related diseases need to be developed. 2) Models have to be made to prove that beneficial effects are actually caused through clearing senescent cells by putative senolytic agents. Without this proof, it would be possible that the candidate agent leads to senescent cell clearance, but that phenotypic improvement is due to ā€œoff-targetā€ effects on non-senescent cells, not directly through senescent cell clearance. 3) Models are needed in which possible side effects of senolytic agents can be tested. It should be noted that even though continual genetic clearance of senescent cells from mice did not lead to any overt side effects during 20Ā months of observation (Baker et al., 2011), there is evidence that cellular senescence has beneficial effects under some circumstances. For example, cellular senescence protects against cancer development, helps to resolve tissue fibrosis during healing, is involved in immune responses, and can contribute to tissue remodeling (Krizhanovsky et al., 2008, Tchkonia et al., 2013, Xue et al., 2007).

Section snippets

Associations between diseases in humans and cellular senescence

Cellular senescence is associated with many of the chronic diseases and disabilities that are the leading drivers of morbidity, mortality, and health costs (Kirkland, 2013a, Tchkonia et al., 2013, Zhu et al., 2014). Senescent cells have been identified at sites of pathology in a number of these conditions and may have systemic effects that predispose to others. These include: 1) metabolic conditions (diabetes, obesity, metabolic syndrome, and age-related lipodystrophy (Minamino et al., 2009,

Potential scenarios for initial proof-of-concept studies of senolytic agents

Initial clinical studies of senolytic agents will most likely involve indications in which short term administration leads to measurable clinical benefits in already symptomatic subjects, rather than studies of lifespan or healthspan. The first clinical studies may need to be publicly funded in academic settings if they involve repurposed agents that are off-patent. Existing agents still under patent, patentable methods of administration (e.g., aerosol, topically, or ophthalmic drops), novel

Animal models of cellular senescence-associated diseases

Animal models reflective of the potential indications for senolytics in humans considered above are needed for the preclinical studies required before proceeding to proof-of-principle human trials. In some cases, genetically modified mice or relevant disease-inducing genetic, pharmacological, or dietary manipulations are available. However, in many cases there are either no models or only ones with imperfections. In the case of human progerias or other syndromes that result from single gene

Conclusions

Indications we feel could be particularly promising for initial proof-of-principle clinical studies as senolytic or SASP-protective agents become available will be in mitigating short- or long-term effects of chemotherapy or radiation, aerosol delivery for idiopathic pulmonary fibrosis, treatment of primary biliary cirrhosis, and injection for osteoarthritis. Disease-emulating animal models reflecting each of these conditions, proof-of-concept testing in animals bred by crosses between these

Conflicts of interest

The authors and Mayo Clinic have a financial interest related to this research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.

Acknowledgments

The authors wish to acknowledge the assistance of J. Armstrong in preparing this manuscript. Support was provided by NIH grants AG013975 and AG044396 (Geroscience Network). The authors are grateful for advice and conversations about strategies for translating agents that affect fundamental aging mechanisms into clinical interventions with colleagues during the retreat series supported by the Geroscience Network.

References (83)

  • P.B. Liton et al.

    Cellular senescence in the glaucomatous outflow pathway

    Exp. Gerontol.

    (2005)
  • D. Munoz-Espin et al.

    Programmed cell senescence during mammalian embryonic development

    Cell

    (2013)
  • T. Qu et al.

    Upregulated ex vivo expression of stress-responsive inflammatory pathway genes by LPS-challenged CD14(+) monocytes in frail older adults

    Mech. Ageing Dev.

    (2009)
  • K. Rockwood et al.

    Frailty defined by deficit accumulation and geriatric medicine defined by frailty

    Clin. Geriatr. Med.

    (2011)
  • J.H. Ryu et al.

    Idiopathic pulmonary fibrosis: evolving concepts

    Mayo Clin. Proc.

    (2014)
  • M. Storer et al.

    Senescence is a developmental mechanism that contributes to embryonic growth and patterning

    Cell

    (2013)
  • R.A. Torres et al.

    Aging and HIV/AIDS: pathogenetic role of therapeutic side effects

    Lab. Investig.

    (2014)
  • J.D. Walston et al.

    Inflammation and stress-related candidate genes, plasma interleukin-6 levels, and longevity in older adults

    Exp. Gerontol.

    (2009)
  • Q.A. Wang et al.

    The AdipoChaser mouse: a model tracking adipogenesis in vivo

    Adipocyte

    (2014)
  • K. Aoshiba et al.

    Senescence hypothesis for the pathogenetic mechanism of chronic obstructive pulmonary disease

    Proc. Am. Thorac. Soc.

    (2009)
  • D.J. Baker et al.

    Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency

    Nat. Cell Biol.

    (2008)
  • D.J. Baker et al.

    Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders

    Nature

    (2011)
  • K. Bandeen-Roche et al.

    Phenotype of frailty: characterization in the women's health and aging studies

    J. Gerontol. A Biol. Sci. Med. Sci.

    (2006)
  • K. Bandeen-Roche et al.

    Measuring systemic inflammatory regulation in older adults: evidence and utility

    Rejuvenation Res.

    (2009)
  • P.J. Barnes

    New anti-inflammatory targets for chronic obstructive pulmonary disease

    Nat. Rev. Drug Discov.

    (2013)
  • E.K. Benson et al.

    Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence

    J. Cell Sci.

    (2010)
  • J. Campisi et al.

    Cellular senescence: when bad things happen to good cells

    Nat. Rev. Mol. Cell Biol.

    (2007)
  • P. Castro et al.

    Cellular senescence in the pathogenesis of benign prostatic hyperplasia

    Prostate

    (2003)
  • Q. Chen et al.

    DNA damage drives accelerated bone aging via an NF-kappaB-dependent mechanism

    J. Bone Miner. Res.

    (2013)
  • S.J. Chinta et al.

    Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson's disease?

    J. Intern. Med.

    (2013)
  • S.H. Choi et al.

    A three-dimensional human neural cell culture model of Alzheimer's disease

    Nature

    (2014)
  • M.E. Clements et al.

    Increased cellular senescence and vascular rarefaction exacerbate the progression of kidney fibrosis in aged mice following transient ischemic injury

    PLoS One

    (2013)
  • F.G. De Felice et al.

    Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

    Diabetes

    (2014)
  • M. Eren et al.

    Role of plasminogen activator inhibitor-1 in senescence and aging

    Semin. Thromb. Hemost.

    (2014)
  • M. Eren et al.

    PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice

    Proc. Natl. Acad. Sci. U. S. A.

    (2014)
  • L. Ferrucci et al.

    Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report

    J. Am. Geriatr. Soc.

    (2004)
  • L.P. Fried et al.

    Frailty in older adults: evidence for a phenotype

    J. Gerontol. A Biol. Sci. Med. Sci.

    (2001)
  • S. Ganesan et al.

    Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression

    Respir. Res.

    (2010)
  • T.E. Golde et al.

    Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases

    Alzheimers Res. Ther.

    (2009)
  • D.P. Goldman et al.

    Substantial health and economic returns from delayed aging may warrant a new focus for medical research

    Health Aff. (Millwood)

    (2013)
  • V.C. Gray-Schopfer et al.

    Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

    Br. J. Cancer

    (2006)
  • Cited by (0)

    View full text